Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday.
Outside advisers to the Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a “rescue therapy” after a doubling of stroke risk was seen in a study of 4,000 patients with mild to moderate kidney disease. The panel recommended more studies to better explain which patients benefit from Aranesp and what dosing is ideal.
Aranesp sales have fallen by a third since 2006 over safety concerns, and doctors have curbed use in kidney patients since the stroke risks were reported last year.
•CLICK HERE to read the Bloomberg News story.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- FDA Sets Anemia Drug Panel Date
- Amgen Stock Stable Despite Bad News Tied to Drug
- FDA Mulling Anemia Drug Dose Changes
- Study Could Mitigate Amgen Drug's Health Risks
- FDA Approves Competitor to Amgen’s Anemia Drugs
- Boston Hospitals Cuts Use of Amgen Drug
- Fresh Concerns On Anemia Drugs
- Court Dismisses Lawsuit Against Amgen